

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal635jle

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|------|---------|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | JAN 17 | Pre-1988 INPI data added to MARPAT |
| NEWS | 4 | FEB 21 | STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results |
| NEWS | 5 | FEB 22 | The IPC thesaurus added to additional patent databases on STN |
| NEWS | 6 | FEB 22 | Updates in EPFULL; IPC 8 enhancements added |
| NEWS | 7 | FEB 27 | New STN AnaVist pricing effective March 1, 2006 |
| NEWS | 8 | MAR 03 | Updates in PATDPA; addition of IPC 8 data without attributes |
| NEWS | 9 | MAR 22 | EMBASE is now updated on a daily basis |
| NEWS | 10 | APR 03 | New IPC 8 fields and IPC thesaurus added to PATDPAFULL |
| NEWS | 11 | APR 03 | Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL |
| NEWS | 12 | APR 04 | STN AnaVist \$500 visualization usage credit offered |
| NEWS | 13 | APR 12 | LINSPEC, learning database for INSPEC, reloaded and enhanced |
| NEWS | 14 | APR 12 | Improved structure highlighting in FQHIT and QHIT display in MARPAT |
| NEWS | 15 | APR 12 | Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected |
| NEWS | 16 | MAY 10 | CA/CAPLUS enhanced with 1900-1906 U.S. patent records |
| NEWS | 17 | MAY 11 | KOREAPAT updates resume |
| NEWS | 18 | MAY 19 | Derwent World Patents Index to be reloaded and enhanced |
| NEWS | 19 | MAY 30 | IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2 |
| NEWS | 20 | MAY 30 | The F-Term thesaurus is now available in CA/CAPLUS |
| NEWS | 21 | JUN 02 | The first reclassification of IPC codes now complete in INPADOC |
| NEWS | EXPRESS | | FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/ |
| NEWS | HOURS | | STN Operating Hours Plus Help Desk Availability |
| NEWS | LOGIN | | Welcome Banner and News Items |
| NEWS | IPC8 | | For general information regarding STN implementation of IPC 8 |
| NEWS | X25 | | X.25 communication option no longer available after June 2006 |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:27:24 ON 06 JUN 2006

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:27:41 ON 06 JUN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2006 HIGHEST RN 886840-90-0

DICTIONARY FILE UPDATES: 5 JUN 2006 HIGHEST RN 886840-90-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s human growth hormone receptor

4979340 HUMAN

6505 HUMANS

4985844 HUMAN

(HUMAN OR HUMANS)

22268 GROWTH

10688 HORMONE

87 HORMONES

10688 HORMONE

(HORMONE OR HORMONES)

101271 RECEPTOR

872 RECEPTORS

101918 RECEPTOR

(RECEPTOR OR RECEPTORS)

L1 23 HUMAN GROWTH HORMONE RECEPTOR

(HUMAN (W) GROWTH (W) HORMONE (W) RECEPTOR)

=> file caplus, uspatfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

19.48

19.69

FILE 'CAPLUS' ENTERED AT 17:28:05 ON 06 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:28:05 ON 06 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1 and (antisense or siRNA or RNAi or dsRNA or ribozyme or triplex or
oligonucleotide)

L2 2 FILE CAPLUS

L3 3 FILE USPATFULL

TOTAL FOR ALL FILES

L4 5 L1 AND (ANTISENSE OR SIRNA OR RNAI OR DSRNA OR RIBOZYME OR TRIPL
EX OR OLIGONUCLEOTIDE)

=> d ibib abs 1-5 fhistr

'FHISTR' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ibib abs fhistr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1335158 CAPLUS

DOCUMENT NUMBER: 144:81464

TITLE: **Oligonucleotides** specific to growth hormone
receptor for modulation of growth hormone receptor
and/or insulin-like growth factor expression, and
therapeutic and diagnostic uses

INVENTOR(S): Tachas, George; Dobie, Kenneth W.; Jain, Ravi; Belyea,
Christopher I.; Heffernan, Mark A.

PATENT ASSIGNEE(S): Australia

SOURCE: U.S. Pat. Appl. Publ., 132 pp., Cont.-in-part of U.S.
Ser. No. 789,526.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|-------------|
| US 2005282761 | A1 | 20051222 | US 2004-927466 | 20040825 |
| US 2004253723 | A1 | 20041216 | US 2004-789526 | 20040226 |
| PRIORITY APPLN. INFO.: | | | US 2003-451455P | P 20030228 |
| | | | US 2003-490230P | P 20030725 |
| | | | US 2004-789526 | A2 20040226 |

AB The invention provides **antisense oligonucleotide**
compsn., which hybridize with nucleic acid encoding growth hormone
receptor. The **oligonucleotides** included chimeric
oligonucleotides having phosphorothioate internucleoside linkages,
sugar moiety, or modified nucleobase, such as 5-methylcytosine. Methods
of using these comps. and compds. for modulating the expression of growth
hormone receptor (GHR) and/or insulin like growth factor-I (IGF-I) and for
diagnosis and treatment of disease associated with expression of GHR and/or
IGF-I are also provided. Diagnostic methods and kits including
GHR-specific primers and probes are also provided.

IT **872063-53-1**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(nucleotide sequence; **oligonucleotides** specific to growth hormone receptor (GHR) for modulation of GHR and/or insulin-like growth factor expression, and therapeutic and diagnostic uses)

RN 872063-53-1 CAPLUS

CN DNA (human growth hormone receptor cDNA plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:756831 CAPLUS

DOCUMENT NUMBER: 141:271997

TITLE: Methods for the synthesis and screening of insulin-like growth factor-I (IGF-I) and growth hormone receptor (GHR) modulators and therapeutic uses thereof

INVENTOR(S): Tachas, George; Dobie, Kenneth

PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2004078922 | A2 | 20040916 | WO 2004-US5896 | 20040227 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| US 2004253723 | A1 | 20041216 | US 2004-789526 | 20040226 |
| AU 2004217508 | A1 | 20040916 | AU 2004-217508 | 20040227 |
| CA 2517101 | AA | 20040916 | CA 2004-2517101 | 20040227 |

PRIORITY APPLN. INFO.:

| | | |
|-----------------|---|----------|
| US 2003-451455P | P | 20030228 |
| US 2003-490230P | P | 20030725 |
| US 2004-789526 | A | 20040226 |
| WO 2004-US5896 | W | 20040227 |

AB Compds., compns. and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compns. comprise **oligonucleotides**, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compds. for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

IT 757999-69-2

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; methods for synthesis and screening of insulin-like growth factor-I (IGF-I) and growth hormone receptor (GHR) oligonucleotidic modulators and therapeutic uses thereof)

RN 757999-69-2 CAPLUS

CN DNA (human growth hormone receptor plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2005:324849 USPATFULL

TITLE: Modulation of growth hormone receptor expression and

INVENTOR(S): insulin-like growth factor expression
Tachas, George, Melbourne, AUSTRALIA
Dobie, Kenneth W., Del Mar, CA, UNITED STATES
Jain, Ravi, Carlsbad, CA, UNITED STATES
Belyea, Christopher I., Melbourne, AUSTRALIA
Heffernan, Mark A., Melbourne, AUSTRALIA

| | NUMBER | KIND | DATE |
|-----------------------|--|------|---------------|
| PATENT INFORMATION: | US 2005282761 | A1 | 20051222 |
| APPLICATION INFO.: | US 2004-927466 | A1 | 20040825 (10) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 2004-789526, filed on 26 Feb 2004, PENDING | | |

| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 2003-451455P | 20030228 (60) |
| | US 2003-490230P | 20030725 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | KNOBBE, MARTENS, OLSON & BEAR, LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US | |
| NUMBER OF CLAIMS: | 48 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 6871 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise **oligonucleotides**, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **872063-53-1**
(nucleotide sequence; oligonucleotides specific to growth hormone receptor (GHR) for modulation of GHR and/or insulin-like growth factor expression, and therapeutic and diagnostic uses)
RN 872063-53-1 USPTFULL
CN DNA (human growth hormone receptor cDNA plus flanks) (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L4 ANSWER 4 OF 5 USPTFULL on STN
ACCESSION NUMBER: 2004:321070 USPTFULL
TITLE: Modulation of growth hormone receptor expression and insulin-like growth factor expression
INVENTOR(S): Tachas, George, Melbourne, AUSTRALIA
Dobie, Kenneth W., Del Mar, CA, UNITED STATES
Jain, Ravi, Carlsbad, CA, UNITED STATES
Belyea, Christopher, Melbourne, AUSTRALIA
Heffernan, Mark A., Melbourne, AUSTRALIA
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., Carlsbad, CA, 92008 (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2004253723 | A1 | 20041216 |
| APPLICATION INFO.: | US 2004-789526 | A1 | 20040226 (10) |

| NUMBER | DATE |
|--------|------|
| | |

PRIORITY INFORMATION: US 2003-451455P 20030228 (60)
US 2003-490230P 20030725 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FENWICK & WEST LLP, 801 CALIFORNIA STREET, MOUNTAIN
VIEW, CA, 94014
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 6798

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise **oligonucleotides**, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 757999-69-2

(nucleotide sequence; methods for synthesis and screening of insulin-like growth factor-I (IGF-I) and growth hormone receptor (GHR) oligonucleotidic modulators and therapeutic uses thereof)

RN 757999-69-2 USPTFULL

CN DNA (human growth hormone receptor plus flanks) (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L4 ANSWER 5 OF 5 USPTFULL on STN

ACCESSION NUMBER: 2004:94203 USPTFULL

TITLE: Binding agent

INVENTOR(S): Ross, Richard, Sheffield, UNITED KINGDOM
Artymiuk, Peter, Sheffield, UNITED KINGDOM
Sayers, Jon, Sheffield, UNITED KINGDOM

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2004071655 | A1 | 20040415 |
| APPLICATION INFO.: | US 2003-311473 | A1 | 20030718 (10) |
| | WO 2001-GB2645 | | 20010618 |

| | NUMBER | DATE |
|-----------------------|--|----------|
| PRIORITY INFORMATION: | GB 2000-14765 | 20000616 |
| | GB 2001-5969 | 20010310 |
| | GB 2001-6487 | 20010316 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300 | |
| NUMBER OF CLAIMS: | 42 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 28 Drawing Page(s) | |
| LINE COUNT: | 1371 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to agents which bind to cell surface receptors; methods to manufacture said agents; therapeutic compositions comprising said agents; and screening methods to identify novel agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 382709-20-8

(nucleotide sequence; chimeric binding agent comprising cytokine, linker and cytokine receptor and uses in modulating receptor activity and therapy)

RN 382709-20-8 USPATFULL
CN DNA (synthetic human somatotropin fusion protein with synthetic human growth hormone receptor-specifying) (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

=> d his

(FILE 'HOME' ENTERED AT 17:27:24 ON 06 JUN 2006)

FILE 'REGISTRY' ENTERED AT 17:27:41 ON 06 JUN 2006

L1 23 S HUMAN GROWTH HORMONE RECEPTOR

FILE 'CAPLUS, USPATFULL' ENTERED AT 17:28:05 ON 06 JUN 2006

L2 2 FILE CAPLUS

L3 3 FILE USPATFULL

TOTAL FOR ALL FILES

L4 5 S L1 AND (ANTISENSE OR SIRNA OR RNAI OR DSRNA OR RIBOZYME OR TR

=> s l1

L5 12 FILE CAPLUS

L6 4 FILE USPATFULL

TOTAL FOR ALL FILES

L7 16 L1

=> dup rem l7

PROCESSING COMPLETED FOR L7

L8 15 DUP REM L7 (1 DUPLICATE REMOVED)

=> d ibib abs 1-15

L8 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:1335158 CAPLUS

DOCUMENT NUMBER: 144:81464

TITLE: Oligonucleotides specific to growth hormone receptor for modulation of growth hormone receptor and/or insulin-like growth factor expression, and therapeutic and diagnostic uses

INVENTOR(S): Tachas, George; Dobie, Kenneth W.; Jain, Ravi; Belyea, Christopher I.; Heffernan, Mark A.

PATENT ASSIGNEE(S): Australia

SOURCE: U.S. Pat. Appl. Publ., 132 pp., Cont.-in-part of U.S. Ser. No. 789,526.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|-------------|
| US 2005282761 | A1 | 20051222 | US 2004-927466 | 20040825 |
| US 2004253723 | A1 | 20041216 | US 2004-789526 | 20040226 |
| PRIORITY APPLN. INFO.: | | | US 2003-451455P | P 20030228 |
| | | | US 2003-490230P | P 20030725 |
| | | | US 2004-789526 | A2 20040226 |

AB The invention provides antisense oligonucleotide compns., which hybridize with nucleic acid encoding growth hormone receptor. The oligonucleotides included chimeric oligonucleotides having phosphorothioate internucleoside linkages, sugar moiety, or modified nucleobase, such as 5-methylcytosine. Methods of using these compns. and compds. for modulating the expression of growth hormone receptor (GHR) and/or insulin like growth factor-I (IGF-I) and for diagnosis and treatment of disease associated with expression

of GHR and/or IGF-I are also provided. Diagnostic methods and kits including GHR-specific primers and probes are also provided.

L8 ANSWER 2 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2005:69436 USPATFULL
TITLE: Glycosylphosphatidylinositol containing polypeptides
INVENTOR(S): Ross, Richard, Sheffield, UNITED KINGDOM

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2005059577 | A1 | 20050317 |
| APPLICATION INFO.: | US 2004-492403 | A1 | 20040413 (10) |
| | WO 2002-GB4665 | | 20021011 |

| | NUMBER | DATE |
|-----------------------|---|----------|
| PRIORITY INFORMATION: | GB 2001-24620 | 20011013 |
| | GB 2002-904 | 20020116 |
| | GB 2002-18889 | 20020814 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300 | |
| NUMBER OF CLAIMS: | 29 | |
| EXEMPLARY CLAIM: | CLM-01-27 | |
| NUMBER OF DRAWINGS: | 25 Drawing Page(s) | |
| LINE COUNT: | 1521 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to polypeptides which comprise a receptor binding domain of a cytokine and a domain which includes a signal sequence for the attachment of glycosylphosphatidylinositol (GPI) anchors. The invention also relates to methods to manufacture the polypeptides, nucleic acids molecules encoding the polypeptides and therapeutic compositions comprising the polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:878488 CAPLUS
DOCUMENT NUMBER: 141:344597
TITLE: Chimeric proteins containing cytokine receptor binding domain and glycosylphosphatidylinositol anchor and their therapeutic uses
INVENTOR(S): Ross, Richard; Sayers, Jon; Artymiuk, Peter
PATENT ASSIGNEE(S): Asterion Limited, UK
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2004090135 | A2 | 20041021 | WO 2004-GB1572 | 20040407 |
| WO 2004090135 | A3 | 20050428 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, | | | |

SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

EP 1616010 A2 20060118 EP 2004-726219 20040407

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.: GB 2003-8088 A 20030409
GB 2003-24235 A 20031016
WO 2004-GB1572 W 20040407

AB The present invention relates to polypeptides which comprise a ligand-binding domain of a cytokine receptor fused with a signal sequence for the attachment of glycosylphosphatidylinositol (GPI) anchors. GPI-anchors are post-translational modifications to proteins that add glycosylphosphatidylinositol which enable these proteins to anchor to the extracellular side of cell membranes. 1B1-GPI was constructed, in which GH was linked through its C-terminus to the extracellular domain of the GH receptor and then linked to the GPI signal sequence. 1C1-GPI was also constructed, in which a tandem of GH was linked through the second GH C-terminus to the GPI signal sequence. The invention provides vectors and CHO-K1 cells for expressing GHBP-GPI.

L8 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:756831 CAPLUS

DOCUMENT NUMBER: 141:271997

TITLE: Methods for the synthesis and screening of insulin-like growth factor-I (IGF-I) and growth hormone receptor (GHR) modulators and therapeutic uses thereof

INVENTOR(S): Tachas, George; Dobie, Kenneth

PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2004078922 | A2 | 20040916 | WO 2004-US5896 | 20040227 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| US 2004253723 | A1 | 20041216 | US 2004-789526 | 20040226 |
| AU 2004217508 | A1 | 20040916 | AU 2004-217508 | 20040227 |
| CA 2517101 | AA | 20040916 | CA 2004-2517101 | 20040227 |

PRIORITY APPLN. INFO.: US 2003-451455P P 20030228
US 2003-490230P P 20030725
US 2004-789526 A 20040226
WO 2004-US5896 W 20040227

AB Compds., compns. and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compns. comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compds. for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

L8 ANSWER 5 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:321070 USPATFULL

TITLE: Modulation of growth hormone receptor expression and
insulin-like growth factor expression
INVENTOR(S): Tachas, George, Melbourne, AUSTRALIA
Dobie, Kenneth W., Del Mar, CA, UNITED STATES
Jain, Ravi, Carlsbad, CA, UNITED STATES
Belyea, Christopher, Melbourne, AUSTRALIA
Heffernan, Mark A., Melbourne, AUSTRALIA
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., Carlsbad, CA, 92008
(non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2004253723 | A1 | 20041216 |
| APPLICATION INFO.: | US 2004-789526 | A1 | 20040226 (10) |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 2003-451455P | 20030228 (60) |
| | US 2003-490230P | 20030725 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | FENWICK & WEST LLP, 801 CALIFORNIA STREET, MOUNTAIN VIEW, CA, 94014 | |
| NUMBER OF CLAIMS: | 45 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 6798 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds, compositions and methods are provided for modulating the
expression of growth hormone receptor and/or insulin like growth
factor-I (IGF-I). The compositions comprise oligonucleotides, targeted
to nucleic acid encoding growth hormone receptor. Methods of using these
compounds for modulation of growth hormone receptor expression and for
diagnosis and treatment of disease associated with expression of growth
hormone receptor and/or insulin-like growth factor-I are provided.
Diagnostic methods and kits are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2004:94203 USPATFULL
TITLE: Binding agent
INVENTOR(S): Ross, Richard, Sheffield, UNITED KINGDOM
Artymiuk, Peter, Sheffield, UNITED KINGDOM
Sayers, Jon, Sheffield, UNITED KINGDOM

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2004071655 | A1 | 20040415 |
| APPLICATION INFO.: | US 2003-311473 | A1 | 20030718 (10) |
| | WO 2001-GB2645 | | 20010618 |

| | NUMBER | DATE |
|-----------------------|--|----------|
| PRIORITY INFORMATION: | GB 2000-14765 | 20000616 |
| | GB 2001-5969 | 20010310 |
| | GB 2001-6487 | 20010316 |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300 | |
| NUMBER OF CLAIMS: | 42 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 28 Drawing Page(s) | |
| LINE COUNT: | 1371 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to agents which bind to cell surface receptors; methods to manufacture said agents; therapeutic compositions comprising said agents; and screening methods to identify novel agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:180984 CAPLUS

DOCUMENT NUMBER: 140:194483

TITLE: Chimeric proteins containing cytokine receptor binding domain and glycosylphosphatidylinositol-containing signaling peptide and their therapeutic uses

INVENTOR(S): Ross, Richard

PATENT ASSIGNEE(S): Asterion Ltd., UK

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2003034275 | A2 | 20030424 | WO 2002-GB4665 | 20021011 |
| WO 2003034275 | A3 | 20031127 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| GB 2380735 | A1 | 20030416 | GB 2001-24620 | 20011013 |
| CA 2494706 | AA | 20030424 | CA 2002-2494706 | 20021011 |
| JP 2005505307 | T2 | 20050224 | JP 2003-536934 | 20021011 |
| US 2005059577 | A1 | 20050317 | US 2004-492403 | 20040413 |
| PRIORITY APPLN. INFO.: | | | GB 2001-24620 | A 20011013 |
| | | | GB 2002-904 | A 20020116 |
| | | | GB 2002-18889 | A 20020814 |
| | | | WO 2002-GB4665 | W 20021011 |

AB The present invention relates to polypeptides which comprise a cytokine-binding domain of a cytokine receptor fused with a signal sequence for the attachment of glycosylphosphatidylinositol (GPI) anchors. The cytokine receptor variants lack a cytoplasmic domain and therefore do not have the capability to signal. The provision of a GPI-anchor domain means the variant inserts into membranes and acts as an effective inhibitor of GH signaling by competing for circulating cytokine and binding cytokine at the cell surface in a heterodimeric complex that consists of the chimeric truncated GPI anchored receptor, cytokine, and the native receptor. In addition, truncated GPI-anchored receptor generates a large amount of soluble receptor which will bind its ligand. In a preferred embodiment, the chimeric protein acts as an antagonist following local or transgenic expression through gene therapy. Thus, the cDNA extracellular domain of human growth hormone receptor (bases 98-834 of GenBank X06562) is ligated into a vector (pAc6-LP-MCS-GPI) containing the Dictyostelium actin 6 gene promoter, a Dictyostelium signal peptide coding region, multiple, cloning site, and the signal for a GPI anchor, and the construct is transfected into Dictyostelium cells. To demonstrate that growth hormone receptor-GPI can act as a transgenic therapy, the extracellular domain of the growth hormone receptor is cloned upstream of a human GPI signal sequence into a mammalian expression vector.

L8 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:300688 CAPLUS
DOCUMENT NUMBER: 138:315840
TITLE: Preparation of GPI-anchored proteins with cytokine
receptor ligand binding domain and signal sequence
INVENTOR(S): Ross, Richard
PATENT ASSIGNEE(S): Asterion Limited, UK
SOURCE: Brit. UK Pat. Appl., 41 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| GB 2380735 | A1 | 20030416 | GB 2001-24620 | 20011013 |
| CA 2494706 | AA | 20030424 | CA 2002-2494706 | 20021011 |
| WO 2003034275 | A2 | 20030424 | WO 2002-GB4665 | 20021011 |
| WO 2003034275 | A3 | 20031127 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CN 1568330 | A | 20050119 | CN 2002-820277 | 20021011 |
| JP 2005505307 | T2 | 20050224 | JP 2003-536934 | 20021011 |
| US 2005059577 | A1 | 20050317 | US 2004-492403 | 20040413 |
| PRIORITY APPLN. INFO.: | | | GB 2001-24620 | A 20011013 |
| | | | GB 2002-904 | A 20020116 |
| | | | GB 2002-18889 | A 20020814 |
| | | | WO 2002-GB4665 | W 20021011 |

AB The present invention relates to polypeptides which comprise a receptor binding domain of a cytokine and a domain which includes a signal sequence for the attachment of glycosylphosphatidylinositol (GPI) anchors. The invention also relates to methods to manufacture the polypeptides, nucleic acids, mols. encoding the polypeptides and therapeutic compns. by comprising the polypeptides.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:924005 CAPLUS
DOCUMENT NUMBER: 136:49347
TITLE: Chimeric binding agent comprising cytokine, linker and cytokine receptor and uses in modulating receptor activity and therapy
INVENTOR(S): Ross, Richard; Artymiuk, Peter; Sayers, Jon
PATENT ASSIGNEE(S): Asterion Limited, UK
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2001096565 | A2 | 20011220 | WO 2001-GB2645 | 20010618 |
| WO 2001096565 | A3 | 20020801 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2447632 AA 20011220 CA 2001-2447632 20010618
 EP 1290170 A2 20030312 EP 2001-940731 20010618

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004503243 T2 20040205 JP 2002-510682 20010618
 US 2004071655 A1 20040415 US 2003-311473 20030718

PRIORITY APPLN. INFO.: GB 2000-14765 A 20000616
 GB 2001-5969 A 20010310
 GB 2001-6487 A 20010316
 WO 2001-GB2645 W 20010618

AB The invention provides a binding agent comprising a first part capable of binding a ligand binding domain of a receptor linked to a second part comprising a receptor binding domain wherein said binding agent modulates the activity of the receptor. The inventors link growth hormone (GH), through its C-terminal and a linker to the N-terminus of the SD100 domain of growth hormone receptor (GHR). By varying the length of the linker inventors define a mol. that has the flexibility to allow binding of GH through site 1 to full length receptor at the cell surface. The invention also relates to methods, vectors and host cells for production of said chimeric binding agent.

L8 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:322773 CAPLUS

DOCUMENT NUMBER: 136:32454

TITLE: Organization and evolution of the human growth hormone receptor gene 5'-flanking region

AUTHOR(S): Goodyer, C. G.; Zogopoulos, G.; Schwartzbauer, G.; Zheng, H.; Hendy, G. N.; Menon, R. K.

CORPORATE SOURCE: Departments of Pediatrics, Medicine, McGill University, Montreal, QC, H3Z 2Z3, Can.

SOURCE: Endocrinology (2001), 142(5), 1923-1934
 CODEN: ENDOAO; ISSN: 0013-7227

PUBLISHER: Endocrine Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Previous studies have identified eight variant human GH receptor (hGHR) mRNA (mRNAs; V1-V8), that differ in their 5'-untranslated regions (5'UTRs) but splice into the same site just upstream of the translation start site in exon 2; thus, they encode the same protein. Here we report a novel variant, V9, and describe the mapping of all nine 5'UTR sequences within 40 kb upstream of exon 2. A cluster of three sequences, V2-V9-V3 (termed module A), lies furthest 5', and approx. 16 kb downstream is a second cluster of four exons, V7-V1-V4-V8 (module B). V6 is midway between modules A and B. Module B is about 18 kb upstream of V5, which lies adjacent to exon 2. HGHR expression is under developmental- and tissue-specific regulation, and expression of the variant mRNAs is related to their position within the 5'-flanking region; whereas module A (V2,V9,V3) and V5 variants are widely expressed, module B (V7,V1,V4,V8) and V6 variant mRNAs are detectable only in postnatal liver. Transcriptional start sites for V1 and V9 (representing the two different modules) were identified, showing that postnatal liver-specific expression of V1 is driven from two TAT boxes, whereas the ubiquitous V9 transcript has a single start site and a TATA-less promoter. V9 promoter activity was shown by in vivo and in vitro transfection assays, and an NF-Y binding site was demonstrated by electromobility shift assay. Thus, the regulatory regions of the hGHR gene are complex, and the clustering of